Sickle Cell Anemia - Drug Pipeline Landscape, 2022

Sickle Cell Anaemia is a form of the inherited blood disorder, called as sickle cell disease which changes the shape of red blood cells, turns round flexible discs into stiff, rigid and sticky sickle cells that blocks blood flow and oxygen to all parts of the body. As a result, there are low healthy red blood cells leads to develop Anaemia, hence the condition is Sickle Cell Anemia.

To know more about Sickle Cell Anemia's pipeline, visit - https://www.globalinsightservices.com/reports/sickle-cell-anemia-drug-pipeline-landscape-2022/

The most common cause of Sickle Cell Anaemia is inheritance of the disease from the biological parents or changes in the gene which produces the haemoglobin, the iron-rich compound in red blood cells.

Symptoms include Anaemia, pain episodes, infections, swelling, delayed growth and vision related issues.

Doctors most often diagnose Sickle Cell Anaemia by blood tests, prenatal genetic screening.

The most common treatments for Sickle Cell Anemia are medications aimed to avoid pain episodes and prevents complications, blood transfusions and stem cell transplantation.

To Remain 'Ahead' Of Your Competitors, Request for A Sample - https://www.globalinsightservices.com/request-sample/GIS31105

Key Players
Afimmune Biopharma Ltd
Agios Pharmaceuticals Inc
Aruvant Sciences GmbH
Ascentage Pharma Group Inc
Astellas Pharma Inc
Aviceda Therapeutics Inc
Bausch Health Americas Inc
Beam Therapeutics Inc
Bluebird bio
Brooklyn ImmunoTherapeutics Inc
C4X Discovery Holdings Plc
Cell Source Inc
Cellectis

Report Segmentation
Assessment by Stage of Development
Assessment by Companies
Assessment by Target
Assessment by Mechanism of Action
Assessment by Molecule Type
Assessment by Route of Administration

Get Customized Report as Per Your Requirement - https://www.globalinsightservices.com/request-customization/GIS31105

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

For In-Depth Competitive Analysis, Purchase this Report - https://www.globalinsightservices.com/inquiry-before-buying/GIS31105

With Global Insight Services, you receive:
• 10-year forecast to help you make strategic decisions
• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Excel data pack included with all report purchases
• Robust and transparent research methodology

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm
headquartered in Delaware, US. We are committed to providing our clients
with highest quality data, analysis, and tools to meet all their market research
needs. With GIS, you can be assured of the quality of the deliverables, robust
and transparent research methodology, and superior service.

This release was published on openPR.